HYBIO(SZ:300199)2022-12-06 23:36Group 1: International Market Strategy - The company has established a dual-driven strategy for overseas development, focusing on both raw material exports and formulation exports [2][3] - In 2016, the company plans to continue applying for ANDA for key products like Glatiramer Acetate and Liraglutide to deepen its international market presence [3][4] - The company has been seeking new models and development paths for internationalization, including strategic cooperation with foreign companies [3] Group 2: Financial Performance - In 2015, the overseas revenue reached 139 million CNY, a year-on-year increase of 49.85%; raw materials contributed 53 million CNY, with a growth of 90.51% [3] - In Q1 2016, raw material revenue was 48 million CNY, showing a staggering year-on-year growth of 5,783.80% [3] - The main contributors to overseas sales were Glatiramer Acetate and Liraglutide, both of which are in the golden period for generic drug applications [3] Group 3: Product Development and Market Expansion - The company has successfully launched Carboprost Tromethamine, a long-acting oxytocin analog, which has shown significant clinical effectiveness and is widely recognized [4] - Following the acquisition of Chengji Pharmaceutical, the company has implemented a comprehensive management team to enhance internal integration and production capacity [4] - The company aims to leverage Chengji Pharmaceutical's production scale and cost advantages to achieve nationwide production layout and expand sales [4]